Page 333 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 17 Vasoactive Peptides 319

Kinins Vasoactive Intestinal Peptide
Bork K: A decade of change: Recent developments in pharmacotherapy of heredi- Paulis L et al: New developments in the pharmacological treatment of hyper-
tary angioedema (HAE). Clin Rev Allergy Immunol 2016;51:183. tension: Dead-end or a glimmer at the horizon? Curr Hypertens Rep
Cicardi M et al: Ecallantide for the treatment of acute attacks in hereditary angio- 2015;17:557.
edema. N Engl J Med 2010;363:523. White CM et al: Therapeutic potential of vasoactive intestinal peptide and its recep-
Cicardi M et al: Icatibant, a new bradykinin-receptor antagonist, in hereditary tors in neurological disorders. CNS Neurol Disord Drug Targets 2010;9:661.
angioedema. N Engl J Med 2010;363:532.
Pathak M et al: Structure of plasma and tissue kallikreins. Thromb Haemost Substance P
2013;109:423.
Taddei S, Bortolotto L: Unraveling the pivotal role of bradykinin in ACE inhibitor Garcia-Recio S, Gascon P: Biological and pharmacological aspects of the NK1-
activity. Am J Cardiovasc Drugs 2016;16:309. receptor. Biomed Res Int 2015;2015:495704.
Mistrova E et al: Role of substance P in the cardiovascular system. Neuropeptides
Vasopressin 2016;58:41.
Munoz M, Covenas R: Involvement of substance P and the NK-1 receptor in
Asfar P et al: Selepressin in septic shock: A step toward decatecholaminization? Crit cancer progression. Peptides 2013;48C:1.
Care Med 2016;44:234.
Boucheix OB et al: Selepressin, a new V1A receptor agonist: Hemodynamic Neurotensin
comparison to vasopressin in dogs. Shock 2013;39:533.
Fujiwara Y et al: The roles of V1a vasopressin receptors in blood pressure homeo- Boules M et al: Diverse roles of neurotensin agonists in the central nervous system.
stasis: A review of studies on V1a receptor knockout mice. Clin Exp Nephrol Front Endocrinol 2013;4:36.
2012;16:30. Hwang JI et al: Phylogenetic history, pharmacological features, and signal
Koshimizu TA et al: Vasopressin V1a and V1b receptors: From molecules to physi- transduction of neurotensin receptors in vertebrates. Ann N Y Acad Sci
ological systems. Physiol Rev 2012;92:1813. 2009;1163:169.
Palmer BF: Vasopressin receptor antagonists. Curr Hypertens Rep 2015;17:510. Osadchii OE: Emerging role of neurotensin in regulation of the cardiovascular
system. Eur J Pharmacol 2015;762:184.
Natriuretic Peptides
Calcitonin Gene-Related Peptide
Anker SD et al: Ularitide for the treatment of acute decompensated heart failure:
From preclinical to clinical studies. Eur Heart J 2015;36:715. Tajti J et al: Migraine and neuropeptides. Neuropeptides 2015;2:19.
Boerrigter G, Burnett JC Jr: Natriuretic peptides renal protective after all? J Am Walker CS et al: Regulation of signal transduction by calcitonin gene-related
Coll Cardiol 2011;58:904. peptide receptors. Trends Pharmacol Sci 2010;31:476.
Federico C: Natriuretic peptide system and cardiovascular disease. Heart Views Wrobel Goldberg S, Silberstein SD: Targeting CGRP: A new era for migraine
2010;11:1. treatment. CNS Drugs 2015;29:443.
Jhund PS, McMurray JJ: The neprilysin pathway in heart failure: A review and
guide on the use of sacubitril/valsartan. Heart 2016;102:1342. Adrenomedullin
Prenner SB et al: Role of angiotensin receptor-neprilysin inhibition in heart failure. Kato J, Kitamura K: Bench-to-bedside pharmacology of adrenomedullin. Eur J
Curr Atheroscler Rep 2016;18:48. Pharmacol 2015;764:140.
Rubattu S et al: Atrial natriuretic peptide and regulation of vascular function in Koyama T et al: Adrenomedullin-RAMP2 system in vascular endothelial cells.
hypertension and heart failure: Implications for novel therapeutic strategies. J Atheroscler Thromb 2015;22:647.
J Hypertens 2013;31:1061. Maguire JJ, Davenport AP: Endothelin@25: new agonists, antagonists, inhibi-
Ruilope LM et al: Blood-pressure reduction with LCZ696, a novel dual- tors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol
acting inhibitor of the angiotensin II receptor and neprilysin: A ran- 2014;171:5555.
domised, double-blind, placebo-controlled, active comparator study. Lancet
2010;375:1255. Nishikimi T et al: Adrenomedullin in cardiovascular disease: A useful biomarker,
its pathological roles and therapeutic application. Curr Protein Pept Sci
Saito Y: Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 2013;14:256.
2010;56:262. Woolley MJ, Conner AC: Comparing the molecular pharmacology of CGRP and
Vilela-Martin JF: Spotlight on valsartan-sacubitril fixed-dose combination for adrenomedullin. Curr Protein Pept Sci 2013;14:358.
heart failure: The evidence to date. Drug Des Devel Ther 2016;10:1627.
Vogel MW, Chen HH: Novel natriuretic peptides: New compounds and new Neuropeptide Y
approaches. Curr Heart Fail Rep 2011;8:22.
Volpe M et al: The natriuretic peptides system in the pathophysiology of Brothers SP, Wahlestedt C: Therapeutic potential of neuropeptide Y (NPY)
heart failure: From molecular basis to treatment. Clin Sci (Lond) receptor ligands. EMBO Mol Med 2010;2:429.
2016;130:57. Pedragosa-Badia X, Stichel J, Beck-Sickinger AG: Neuropeptide Y receptors: How
to get subtype selectivity. Front Endocrinol 2013;4:5.
Endothelins Saraf R et al: Neuropeptide Y is an angiogenic factor in cardiovascular regenera-
tion. Eur J Pharmacol 2016;776:64.
Davenport AP et al: Endothelin. Pharmacol Rev 2016;68:357. Zhu P et al: The role of neuropeptide Y in the pathophysiology of atherosclerotic
Kawanabe Y, Nauli SM: Endothelin. Cell Mol Life Sci 2011;68:195. cardiovascular disease. Int J Cardiol 2016;220:235.
Pulido T et al: Macitentan and morbidity and mortality in pulmonary arterial
hypertension. N Engl J Med 2013;369:809. Urotensin
Sidharta PN, van Giersbergen PL, Dingemanse J: Safety, tolerability, pharma-
cokinetics, and pharmacodynamics of macitentan, an endothelin receptor Chatenet D et al: Update on the urotensinergic system: New trends in receptor
antagonist, in an ascending multiple-dose study in healthy subjects. J Clin localization, activation, and drug design. Front Endocrinol 2013;3:1.
Pharmacol 2013;53:1131. Cheriyan J et al: The effects of urotensin II and urantide on forearm blood
Sitbon O, Morrell N: Pathways in pulmonary arterial hypertension: The future is flow and systemic haemodynamics in humans. Br J Clin Pharmacol
here. Eur Respir Rev 2012;21:321. 2009;68:518.